Biogen (NASDAQ:BIIB) Price Target Raised to $214.00 at Stifel Nicolaus

Posted by Donna Armstrong on Feb 7th, 2026

Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Stifel Nicolaus from $202.00 to $214.00 in a research note released on Friday morning,MarketScreener reports. Stifel Nicolaus currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also commented on BIIB. Robert W. Baird decreased their price target on Biogen from $255.00 to $250.00 in a research report on Friday, October 31st. Morgan Stanley lifted their price target on Biogen from $149.00 to $156.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Citigroup raised their price objective on shares of Biogen from $180.00 to $185.00 and gave the stock a “neutral” rating in a report on Tuesday, January 27th. Oppenheimer increased their price objective on shares of Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, January 30th. Finally, BMO Capital Markets restated a “market perform” rating and set a $196.00 price objective on shares of Biogen in a research report on Friday. Eleven analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $194.23.

View Our Latest Stock Report on BIIB

Biogen Trading Up 8.5%

NASDAQ:BIIB opened at $201.18 on Friday. The stock’s 50-day moving average is $176.94 and its two-hundred day moving average is $156.67. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.72 and a quick ratio of 2.04. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The stock has a market cap of $29.51 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 1.56 and a beta of 0.16.

Biogen (NASDAQ:BIIB – Get Free Report) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The firm’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts forecast that Biogen will post 15.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Priya Singhal sold 748 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the transaction, the insider directly owned 6,271 shares of the company’s stock, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.18% of the stock is currently owned by insiders.

Institutional Trading of Biogen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Elevation Point Wealth Partners LLC purchased a new stake in Biogen during the second quarter valued at $25,000. WPG Advisers LLC grew its stake in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares during the last quarter. Rothschild Investment LLC lifted its stake in Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares during the period. Accredited Wealth Management LLC raised its stake in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares during the period. Finally, Concord Wealth Partners lifted its position in shares of Biogen by 100.0% during the 2nd quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 114 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

Positive Sentiment: Q4 beat on both EPS ($1.99 vs. consensus ~1.72) and revenue ($2.28B vs. ~$2.21B); investors reacted favorably to the upside. BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat ’26 EPS View
Positive Sentiment: Biogen raised FY‑2026 adjusted EPS guidance to $15.25–$16.25, above consensus — a major driver of the rally as it signals stronger full‑year profitability expectations. Biogen forecasts annual profit above estimates as Leqembi sales pick up
Positive Sentiment: Sales of Leqembi and newer launches (Skyclarys, Zurzuvae) showed meaningful growth and helped offset MS declines, supporting upside to future revenue mix and margins. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
Positive Sentiment: Recent analyst support (RBC buy) and favorable coverage helped sentiment alongside the earnings/guidance beat. Biogen (BIIB) Receives a Buy from RBC Capital
Neutral Sentiment: Management released the full earnings slide deck and call transcript — useful for modeling guidance assumptions and product-level trends but not market-moving on its own. Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Negative Sentiment: Core MS franchise continued to decline, driving overall revenue down ~7.2% YoY; management said MS revenue pressures will persist, which limits near‑term top‑line growth. Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide
Negative Sentiment: Some outlets note Biogen “swung to a loss” on certain GAAP measures and expect continued portfolio declines, underlining execution and pricing risks in legacy products. Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles

About Biogen

(Get Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.